🚀 VC round data is live in beta, check it out!
SSY Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for SSY Group and similar public comparables like AprilBio, Mega Lifesciences, Cullinan Therapeutics, Arbutus Biopharma and more.
SSY Group Overview
About SSY Group
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
Founded
2005
HQ
Employees
6.1K
Website
Sectors
Financials (FY)
EV
$1B
SSY Group Financials
SSY Group reported last fiscal year revenue of $738M and EBITDA of $238M.
In the same fiscal year, SSY Group generated $372M in gross profit, $238M in EBITDA, and $136M in net income.
SSY Group P&L
In the most recent fiscal year, SSY Group reported revenue of $738M and EBITDA of $238M.
SSY Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $738M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $372M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 50% | XXX | XXX | XXX |
| EBITDA | — | XXX | $238M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 23% | XXX | XXX | XXX |
| Net Profit | — | XXX | $136M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $304M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SSY Group Stock Performance
SSY Group has current market cap of $919M, and enterprise value of $1B.
Market Cap Evolution
SSY Group's stock price is $0.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $919M | -1.5% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSSY Group Valuation Multiples
SSY Group trades at 1.6x EV/Revenue multiple, and 5.1x EV/EBITDA.
SSY Group Financial Valuation Multiples
As of April 18, 2026, SSY Group has market cap of $919M and EV of $1B.
Equity research analysts estimate SSY Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SSY Group has a P/E ratio of 6.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $919M | XXX | $919M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.3x | XXX | XXX | XXX |
| P/E | — | XXX | 6.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (191.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SSY Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SSY Group Margins & Growth Rates
SSY Group's revenue in the last fiscal year declined by (11%).
SSY Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
SSY Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (12%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SSY Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SSY Group | XXX | XXX | XXX | XXX | XXX | XXX |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Cullinan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arbutus Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MeiraGTx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SSY Group M&A Activity
SSY Group acquired XXX companies to date.
Last acquisition by SSY Group was on XXXXXXXX, XXXXX. SSY Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SSY Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSSY Group Investment Activity
SSY Group invested in XXX companies to date.
SSY Group made its latest investment on XXXXXXXX, XXXXX. SSY Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SSY Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SSY Group
| When was SSY Group founded? | SSY Group was founded in 2005. |
| Where is SSY Group headquartered? | SSY Group is headquartered in China. |
| How many employees does SSY Group have? | As of today, SSY Group has over 6K employees. |
| Who is the CEO of SSY Group? | SSY Group's CEO is Jiguang Qu. |
| Is SSY Group publicly listed? | Yes, SSY Group is a public company listed on HKEX. |
| What is the stock symbol of SSY Group? | SSY Group trades under 02005 ticker. |
| When did SSY Group go public? | SSY Group went public in 2005. |
| Who are competitors of SSY Group? | SSY Group main competitors are AprilBio, Mega Lifesciences, Cullinan Therapeutics, Arbutus Biopharma. |
| What is the current market cap of SSY Group? | SSY Group's current market cap is $919M. |
| What is the current revenue of SSY Group? | SSY Group's last fiscal year revenue is $738M. |
| What is the current EV/Revenue multiple of SSY Group? | Current revenue multiple of SSY Group is 1.6x. |
| Is SSY Group profitable? | No, SSY Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.